New prescription drug makes Fenugreek pill look less like a red pill

FENUGREEK PILLS is being billed as a pill that makes your red pill look like a green pill.

FENUQUIK, a generic name for Fenugreek, is available as a generic version, but it comes in a blue pill that is just as effective as its red counterpart.

The drug has been around since the 1960s and has been touted as a cure for anxiety, depression and other mental disorders.

It’s marketed as a treatment for pain and other conditions, as well as a medication for the prevention of heart attacks and strokes.

But in recent years, there have been a growing number of concerns about its safety.

The Food and Drug Administration (FDA) says it is the most commonly prescribed antidepressant in the world.

The agency’s drug information website says the drug is a partial agonist of serotonin, a neurotransmitter involved in mood, learning and memory.

The website also says that Fenugrees ability to increase serotonin production by up to 90 per cent is thought to contribute to its ability to lower depression.

The pill can be taken for up to 24 hours and can have side effects, such as muscle spasms and nausea, according to the Drug Facts website.

Its popularity is in part due to its effectiveness as a pain reliever and as a sleep aid, which can be used for anxiety and insomnia.

In some cases, Fenugreks side effects are related to its serotonin agonist.

The Drug Facts site says that it may increase blood pressure, increase the risk of strokes and heart attack, and make it harder for people with depression to get better.

“The combination of these effects can result in dangerous side effects such as cardiac arrhythmia, tachycardia, hyperthermia and hypotension,” the website states.

In recent years some experts have argued that Fenogreks efficacy may have been overstated, but the drug has never been subjected to a clinical trial and has never received a major safety study.

In the US, there were 538,828 Fenugres sold in the first six months of 2018, according a report from the Centers for Disease Control and Prevention (CDC).

The drug was approved in April 2018 for the treatment of insomnia and a few other conditions.

The FDA has said that it has been able to obtain approval for use of the drug for insomnia and is waiting for results from a trial to determine whether it will be used more widely.

According to the CDC, the drug’s effectiveness is based on a trial of the pill in two populations, one in which it was used for insomnia, and one in an adult population.

A trial is typically a trial that is conducted in people who have the disease and who are receiving the drug.

The CDC’s analysis said that the safety of Fenugryk is currently unknown.

In a report published in March 2018, the FDA said that there was “no indication that the effectiveness of Fenuq was significantly different from placebo.”

The drug is prescribed to people over age 18 for insomnia or depression, according the FDA.

The company has said it is working with the FDA to provide additional information on its safety and efficacy.

Fenugrin is available in two strengths: one is a generic formulation and the other is a red version.

It comes in two sizes: the generic is 6 mg and the red is 4 mg.

Both are available online, but one is cheaper than the other.

The generic comes in three strengths: generic, red and blue.

The brand name Fenugritts is “FENUGREK.”

The brand names are listed on the generic version of the pills.

The blue version comes in white or pink capsules, while the generic comes with green or blue capsules.

The manufacturer of the blue version says it’s not as effective.

The product has a generic label and a generic bottle number on it.

The white version has the generic label but is not listed on it, and the pink version does not.

The label on the blue pill says it contains 3 mg of Fenogrin, but this is not the dose.

According the FDA, there is no indication that Fenuquay is more effective than placebo in treating depression.

This pill has not been subjected a clinical study.

A number of experts have criticized the safety and effectiveness of the medication, including a number of scientists.

The American Psychological Association, which represents more than 1.2 million psychologists, has said the drug should not be prescribed to anyone under age 18.

“There are no studies to support the efficacy of FenUQ as an antidepressant,” the association wrote in a 2017 statement.

A recent review of published clinical trials of Fenumogrek and other serotonin-enhancing drugs found that some were not adequately powered to control for the influence of other variables.

“Many of these studies found that patients who took FenuQ had better psychological outcomes than those who did not take